Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vertex, Inc.

40.98
-0.0900-0.22%
Volume:438.85K
Turnover:17.87M
Market Cap:6.49B
PE:-144.55
High:41.63
Open:41.43
Low:40.30
Close:41.07
Loading ...

Vertex Pharmaceuticals’ Povetacicept: A Promising Contender in IgA Nephropathy Treatment with Strong Market Potential

TIPRANKS
·
Yesterday

Vertex Pharmaceuticals (VRTX) Gets a Hold from Citi

TIPRANKS
·
Yesterday

Vertex Pharmaceuticals: Strong Performance and Promising Pipeline Drive Buy Rating

TIPRANKS
·
07 Jun

Vertex Pharmaceuticals (VRTX) Receives a Hold from RBC Capital

TIPRANKS
·
07 Jun

Lightstone Ventures, Temasek’s ClavystBio co-lead Allay Therapeutics’ US$57.5 million Series D funding

businesstimes
·
06 Jun

Vertex Minerals Ltd. Advances Towards High-Grade Gold Production

TIPRANKS
·
05 Jun

Vertex Minerals Identifies New Stope Block for Production

TIPRANKS
·
04 Jun

3 No-Brainer Healthcare Stocks to Buy in June

Motley Fool
·
02 Jun

Wall Street Analysts Are Bullish on Top Technology Picks

TIPRANKS
·
02 Jun

4 Monster Stocks to Buy and Hold for the Next Decade

Motley Fool
·
02 Jun

Tasmea to Acquire Electrical Services Provider for Upfront Consideration of Around AU$9 Million

MT Newswires Live
·
02 Jun

Tasmea Ltd. Expands Electrification Services with Vertex Group Acquisition

TIPRANKS
·
02 Jun

2 Top Stocks to Buy Right Now

Motley Fool
·
01 Jun

Vertex Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors

Dow Jones
·
31 May

UBS Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
30 May

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow

Motley Fool
·
28 May

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
28 May

BMO says Eli Lilly ‘well-priced deal’ to expand presence in pain a positive

TIPRANKS
·
27 May

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

StockStory
·
27 May

3 Top Growth Stocks to Buy in the Second Half of 2025

Motley Fool
·
26 May